About this Journal Submit a Manuscript Table of Contents
Sarcoma
Volume 2006 (2006), Article ID 91671, 6 pages
http://dx.doi.org/10.1155/SRCM/2006/91671
Research Article

Clinical Outcomes of Intraoperative Radiation Therapy for Extremity Sarcomas

1Department of Radiation Oncology, Comprehensive Cancer Center, 1600 Divisadero Street, Suite H1031, San Francisco, CA 94143-1708, USA
2Department of Orthopaedic Surgery, Comprehensive Cancer Center, University of California at San Francisco, 1600 Divisadero Street, 4th Floor, San Francisco, CA 94143-1708, USA
3Biostatistics Core, Comprehensive Cancer Center, University of California at San Francisco, 1600 Divisadero Street, Suite H1031, San Francisco, CA 94143-1708, USA

Received 19 May 2005; Accepted 15 December 2005

Copyright © 2006 Quy N. H. Tran et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Purpose. Radiation of extremity lesions, a key component of limb-sparing therapy, presents particular challenges, with significant risks of toxicities. We sought to explore the efficacy of intraoperative radiation therapy (IORT) in the treatment of soft tissue sarcomas of the extremities. Patients. Between 1995 and 2001, 17 patients received IORT for soft tissue sarcomas of the extremities. Indications for IORT included recurrent tumors in a previously radiated field or tumors adjacent to critical structures. Results. Gross total resections were achieved in all 17 patients. Two patients experienced locoregional relapses, six patients recurred at metastatic sites, and one patient died without recurrence. Thirty-six month estimates for locoregional control, disease free survival, and overall survival were 86%, 50%, and 78%, respectively. IORT was extremely well tolerated, with no toxicities referable to IORT. Conclusions. For patients with soft tissue sarcomas of the extremities, IORT used as a boost to EBRT provides excellent local control, with limited acute toxicities.